Landec Corporation reiterated revenue guidance for the full year fiscal 2023. For the year, the company reiterating Lifecore segment revenue of range of $122 million to $126 million (+12% to +15%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 USD | -1.23% | -4.26% | -9.21% |
04-19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
04-01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.21% | 172M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023